BMS looks to RNA splicing to boost immunotherapiesBristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and Share XBMS looks to RNA splicing to boost immunotherapieshttps://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
EU approves Ipsen’s Cabometyx in second line liver cancerThe European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The Share XEU approves Ipsen’s Cabometyx in second line liver cancerhttps://pharmaphorum.com/news/european-commission-cabometyx/
BMS, AbbVie get FDA OK for new myeloma regimenBristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they Share XBMS, AbbVie get FDA OK for new myeloma regimenhttps://pharmaphorum.com/news/bms-abbvie-get-fda-ok-for-new-myeloma-regimen/
BMS and Infinity trial immunotherapy combo in bladder cancerBristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the Share XBMS and Infinity trial immunotherapy combo in bladder cancerhttps://pharmaphorum.com/news/bms-and-infinity-trial-immunotherapy-combo-in-bladder-cancer/
BMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientsBristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal Share XBMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientshttps://pharmaphorum.com/news/bms-opdivoyervoy-could-become-first-choice-for-certain-colorectal-cancer-patients/
Merck aims for first line kidney cancer use for Keytruda comboMerck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing Share XMerck aims for first line kidney cancer use for Keytruda combohttps://pharmaphorum.com/news/merck-aims-for-first-line-kidney-cancer-use-for-keytruda-combo/
BMS Opdivo fails in small cell lung cancerBristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with Share XBMS Opdivo fails in small cell lung cancerhttps://pharmaphorum.com/news/bms-opdivo-fails-in-small-cell-lung-cancer/
BMS invests $12m in cancer immunotherapy tie-up with CompugenBristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could Share XBMS invests $12m in cancer immunotherapy tie-up with Compugenhttps://pharmaphorum.com/news/bms-invests-12m-in-cancer-immunotherapy-tie-up-with-compugen/
